Government Contract Win May Improve Investor Sentiment For SIGA Tech After Disappointing Trial Data: Analyst
Government Contract Win May Improve Investor Sentiment For SIGA Tech After Disappointing Trial Data: Analyst
On Wednesday, SIGA Technologies, Inc. (NASDAQ:SIGA) announced a new contract with the U.S. Department of Defense (DOD) to procure approximately $9 million of TPOXX.
週三，SIGA Technologies，Inc.（納斯達克：SIGA）宣佈與美國國防部（DOD）簽署新合同，採購約900萬美元的TPOXX。
This award is comprised primarily of oral TPOXX, with a small amount of intravenous (IV) TPOXX, and represents the third procurement contract award from the DOD over the past three years.
這一獎項主要包括口服TPOXX和少量靜脈注射（IV）TPOXX，代表着過去三年來從國防部獲得的第三份採購合同獎勵。
The company also received approximately $27 million to develop the post-exposure Prophylaxis indication for oral TPOXX.
該公司還獲得約2700萬美元用於開發口服TPOXX的事後暴露預防適應症。
Also Read: Mpox Variant Sparks Global Concern As Europe, China Ramp Up Screening.
另請閱讀： 歐洲和中國加強檢測工作，Mpox變種引發全球關注。
Inclusive of this award, SIGA currently has approximately $154 million of outstanding oral and IV TPOXX orders, more than 85% of which were generated within the past three months.
包括這一獎項，SIGA目前擁有約15400萬美元的口服和IV TPOXX訂單，其中超過85%是在過去三個月內生成的。
Edison report adds that SIGA continues to advance its growth strategy, with recent contract wins from BARDA and the Department of Defense significantly boosting its order book.
Edison報告補充道，SIGA繼續推進其增長策略，最近從BARDA和國防部贏得的合同顯著提振了其60檔擺盤。
The company is set to deliver IV TPOXX under orders from July 2023 ($25 million), and August 2022 ($8.4 million, of which $17.8 million from a $26 million order was already delivered in the first half of 2024).
該公司將根據2023年7月（2500萬美元）和2022年8月（840萬美元，其中2600萬美元訂單中的1780萬美元已在2024年上半年交付）的訂單交付IV TPOXX。
These are part of approximately $155 million in outstanding TPOXX (oral and IV) orders.
這些是約15500萬美元的未完成TPOXX（口服和IV）訂單的一部分。
SIGA anticipates delivering the remaining August 2022 IV TPOXX order and 80% of the BARDA oral TPOXX order in the second half of 2024.
SIGA預計在2024年下半年交付剩餘的2022年8月IV TPOXX訂單和BARDA口服TPOXX訂單的80%。
While delivery timeline details are yet to be disclosed, Edison Group's report notes that new DoD order to start at least being partially serviced in fiscal year 2025.
雖然交付時間表細節尚未披露，但Edison集團的報告指出，新的國防部訂單將至少在2025財年開始部分服務。
Recently, the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) announced topline results from a preliminary analysis of the PALM 007 trial of tecovirimat for mpox.
最近，美國國立衛生研究院的過敏和傳染病研究所（NIAID）宣佈了對mpox的tecovirimat PALm 007試驗初步分析的頭條結果。
NIAID reported that the study did not meet its primary endpoint of a statistically significant improvement in time to lesion resolution within 28 days post-randomization for patients in the Democratic Republic of the Congo with mpox who were administered SIGA's tecovirimat versus placebo, weighing on the share price.
NIAID報告稱，該研究未達到其主要終點，在剛果民主共和國接受SIGA tecovirimat與安慰劑治療的mpox患者中，28天內病變分辨時間的統計顯著改善，並對股價造成壓力。
Edison analysts expect an improvement in investor sentiment with the recent DoD contract win.
Edison分析師預計，最近的國防部合同獲得將提升投資者情緒。
"We maintain that mpox continues to be an opportunity for SIGA on the heels of the WHO declaration of a global health emergency," the analysts added.
「我們認爲，在世衛組織宣佈全球衛生緊急事件後，mpox仍然是SIGA的機遇，」分析師補充道。
Price Action: SIGA stock is up 4.07% at $9.72 at the last check on Friday.
股價走勢：SIGA股價在上週五最後一次檢查時上漲了4.07%，達到了9.72美元。
- Europe Approves Moderna's RSV Vaccine For Adults 60 And Over.
- 歐洲批准Moderna針對60歲及以上成年人的RSV疫苗。
譯文內容由第三人軟體翻譯。